Skip to main content

Clinical Trials to Treat Childhood Embryonal Tumors

Trials 1-6 of 6

Digoxin for the Treatment of Pediatric and Young Adult Patients with Relapsed Non-SHH, Non-WNT Medulloblastoma
Status: Active
Location: 9 locations
A Peptide Vaccine (PEP-CMV) for the Treatment of Pediatric Patients with Newly Diagnosed High-Grade Glioma and Diffuse Intrinsic Pontine Glioma, or Recurrent, Refractory, or Progressive Medulloblastoma
Status: Active
Location: 6 locations
Cellular Therapy (GPC2-CAR T-Cells) for the Treatment of Children and Young Adults with Relapsed or Refractory Medulloblastoma and other Central Nervous System Embryonal Tumors
Status: Active
Location: 2 locations
Genetically Engineered Cells (C7R-GD2.CAR T Cells) for the Treatment of Patients with GD2-Expressing High Grade Glioma or Diffuse Intrinsic Pontine Glioma, The GAIL-B Trial
Status: Active
Location: 2 locations
PEP-CMV Vaccine plus Nivolumab for the Treatment of Newly Diagnosed or Recurrent Childhood Diffuse Midline Glioma/High-Grade Glioma and Recurrent Childhood Medulloblastoma and Ependymoma, PRiME II Trial
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Testing the Safety, Tolerability and Immunological Effects of SurVaxM in Children and Young Adults with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Status: Temporarily Closed to Accrual
Location: 11 locations